8-K: Cardio Diagnostics Holdings Enacts 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance

Cardio Diagnostics Holdings, Inc. implemented a 1-for-30 reverse stock split, effective May 13, 2025, to meet Nasdaq's minimum bid price requirement.

Summary

• Cardio Diagnostics Holdings, Inc. announced a 1-for-30 reverse stock split of its common stock.
• The reverse stock split became effective immediately after the close of trading on Nasdaq on May 12, 2025, with trading on a post-split basis commencing on May 13, 2025.
• The primary reason for the reverse stock split is to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The reverse stock split was authorized by the company's stockholders on November 15, 2024.
• The Board of Directors approved the 1-for-30 ratio on April 10, 2025.
• As a result, every 30 shares of common stock were combined into one share.
• The number of outstanding shares was reduced from approximately 52 million to approximately 1.7 million.
• The number of authorized shares remains at 300 million.
• Adjustments were made to the company's equity incentive plan, outstanding public and private warrants, and stock options.
• The new CUSIP number for the common stock post-split is 14159C202.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed negatively by the market, suggesting underlying financial challenges. While the company aims to regain compliance, the action itself reflects prior difficulties in maintaining the required stock price.

Positives

• The reverse stock split aims to ensure continued listing on The Nasdaq Capital Market, which could improve investor confidence.
• The company has addressed a compliance issue with Nasdaq.

Negatives

• Reverse stock splits are often viewed negatively by investors as they can indicate financial distress or an attempt to artificially inflate the stock price.
• Existing shareholders experienced a significant reduction in the number of shares they hold.

Risks

• The reverse stock split may not be sufficient to maintain Nasdaq compliance if the stock price does not remain above the minimum bid price.
• Investor perception of the reverse stock split could negatively impact the stock price.
• The company's ability to execute its growth strategy and obtain future financing remains a risk.

Future Outlook

The company aims to maintain its listing on The Nasdaq Capital Market through the reverse stock split. The company will continue to develop and commercialize clinical tests leveraging its AI-driven technology.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in the biotech and healthcare sectors have used similar strategies to maintain compliance and attract investors.

Comparison to Industry Standards

• Many small-cap biotech companies facing similar challenges have implemented reverse stock splits.
• The success of this strategy depends on the company's ability to improve its financial performance and investor confidence following the split.
• Compared to other companies, the 1-for-30 ratio is relatively high, indicating a significant decline in share price prior to the split.

Stakeholder Impact

• Shareholders experienced a reduction in the number of shares they hold.
• The reverse stock split aims to maintain the company's listing, which could benefit stakeholders in the long term.

Next Steps

• The company will monitor its stock price to ensure continued compliance with Nasdaq listing requirements.
• The company will continue to execute its growth strategy and develop its AI-driven technology.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, CDIO, common stock, stock split, Cardio Diagnostics